2-Adamantan-1-yl-2-methyl-azetidine | 888030-17-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Adamantan-1-yl-2-methyl-azetidine
• 英文别名: 2-(1-Adamantyl)-2-methylazetidine
• CAS: 888030-17-9
• 化学式: C₁₄H₂₃N
• 分子量: 205.343
• InChiKey: DXJCPNOXXAOZGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Adamantan-1-yl-2-methyl-azetidine 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  Heterocyclic rimantadine analogues with antiviral activity

  摘要：

  2-(1-Adamantyl)-2-methyl-pyrrolidines 3 and 4, 2-(1-adamatityl)-2-methyl-azetidines 5 and 6, and 2-(1-adamantyl)-2-methyl-aziridines 7 and 8 were synthesized and tested for their antiviral activity against influenza A. Parent molecules 3, 5, and 7 contain the alpha-methyl-1-adimantan-methanamine 2 pharmacophoric moiety (rimantadine). The ring size effect on anti-influenza A activity was investigated. Pyrrolidine 3 was the most potent anti-influenza virus A compound, 9-fold more potent than rimantadine 2, 27-fold more potent than amantadine 1, and 22-fold more potent than ribavirin. Azetidines 5 and 6 were both markedly active against influenza A H2N2 virus, 10- to 20-fold more potent than amantadine. Aziridine 7 was almost devoid of any activity against H2N2 virus but exhibited borderline activity against H3N2 influenza A strain. Thus, it appears that changing the five-, to four- to a three-membered ring results in a drop of activity against influenza A virus. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.12.056
• 作为产物：
  描述：

  4-(tricyclo[3.3.1.1^3,7]dec-1-yl)-4-methyl-2-azetidinone 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 25.0h， 以98%的产率得到2-Adamantan-1-yl-2-methyl-azetidine
  参考文献：
  名称：

  Heterocyclic rimantadine analogues with antiviral activity

  摘要：

  2-(1-Adamantyl)-2-methyl-pyrrolidines 3 and 4, 2-(1-adamatityl)-2-methyl-azetidines 5 and 6, and 2-(1-adamantyl)-2-methyl-aziridines 7 and 8 were synthesized and tested for their antiviral activity against influenza A. Parent molecules 3, 5, and 7 contain the alpha-methyl-1-adimantan-methanamine 2 pharmacophoric moiety (rimantadine). The ring size effect on anti-influenza A activity was investigated. Pyrrolidine 3 was the most potent anti-influenza virus A compound, 9-fold more potent than rimantadine 2, 27-fold more potent than amantadine 1, and 22-fold more potent than ribavirin. Azetidines 5 and 6 were both markedly active against influenza A H2N2 virus, 10- to 20-fold more potent than amantadine. Aziridine 7 was almost devoid of any activity against H2N2 virus but exhibited borderline activity against H3N2 influenza A strain. Thus, it appears that changing the five-, to four- to a three-membered ring results in a drop of activity against influenza A virus. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.12.056

文献信息

• [EN] CANCER TREATMENT BY SENESCENCE INDUCTION FOLLOWED BY A SENOLYTIC<br/>[FR] TRAITEMENT DU CANCER PAR L'INDUCTION DE SÉNESCENCE SUIVIE D'UN SÉNOLYTIQUE
  申请人：UNITY BIOTECHNOLOGY INC

  公开号：WO2021231486A1

  公开（公告）日：2021-11-18

  This invention is based on methods of killing cancer cells by first using either chemotherapeutic agents or radiation treatment to induce senescence in said cancer cells and then subsequently administering a senolytic, such as a Bcl inhibitor, to induce apoptosis of said cancer cell. Formulations of pharmaceutical agents for use according to this invention are also described.